Furthermore, as MEDI2228 upregulates expression of CD38 and NKG2D ligands on the MM cell surface, it increases NK cell immune activity and restores daratumumab-induced ADCC, supporting the combination of CD38- and BCMA-targeted immunotherapies [82]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.